• Phase 1
  • Phase 2
  • Phase 3
  • Market
17 Antibodies available:
Program
Partner
Indication
Phase

Partner

Incyte Corporation*

Indication

Phase

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (L-MIND) (Monjuvi® - U.S. only – accelerated approval)
Phase 1 Phase 2 Phase 3 Market (Current Phase)
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (B-MIND)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Relapsed or refractory follicular or marginal zone lymphoma (FL; MZL) (inMIND)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Diffuse large B-cell lymphoma (DLBCL) (frontMIND)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (COSMOS)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Diffuse large B-cell lymphoma (DLBCL) (firstMIND)
Phase 1 (Current Phase) Phase 2 Phase 3 Market

*Global Collaboration and License Agreement with Incyte Corporation; co-commercialization in the U.S.; Incyte has exclusive commercialization rights outside the U.S.

  • MOR208 (former XmAb®5574)
  • INN: tafasitamab
  • Target: CD19

Felzartamab (MOR202/TJ202)

Partner

I-Mab Biopharma**

Indication

Phase

Multiple myeloma (MM) (combo with lenalidomide)*
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Multiple myeloma (MM)*
Phase 1 Phase 2 (Current Phase) Phase 3 Market

Pelabresib

Partner

 

Indication

Phase

Myelofibrosis (MANIFEST-2)
Phase 1 Phase 2 Phase 3 (Current Phase) Market

Otilimab (MOR103/GSK3196165)

Partner

GlaxoSmithKline

Indication

Phase

Rheumatoid arthritis (contRAst 1-3)*
Phase 1 Phase 2 Phase 3 (Current Phase) Market

*Fully outlicensed to GlaxoSmithKline.

  • A fully human HuCAL antibody
  • Target: GM-CSF

Partner

 

Indication

Phase

Immunoglobulin A Nephropathy (IGNAZ)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Anti-PLA2R-positive membranous nephropathy (New-PLACE)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Anti-PLA2R-positive membranous nephropathy (M-PLACE)
Phase 1 (Current Phase) Phase 2 Phase 3 Market

* Felzartamab (MOR202/TJ202): Sublicensed to I-Mab for development in China, Hong Kong, Macao and Taiwan.

  • A fully human HuCAL antibody
  • Target: CD38

CPI-0209

Partner

 

Indication

Phase

Advanced Solid Tumors / Hematologic Malignancies
Phase 1 Phase 2 (Current Phase) Phase 3 Market

Gantenerumab

Partner

Roche

Indication

Phase

Early Alzheimer's disease (GRADUATE 1+2)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Mild Alzheimer's disease (Marguerite RoAD) (OLE)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Prodromal Alzheimer's disease (Scarlett RoAD) (OLE)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Rollover study on long-term administration of gantenerumab
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Alzheimer's disease (Brain Shuttle Gantenerumab, RG6102)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody
  • Target: Amyloid-beta

Additional Information:

Ianalumab (VAY736)

Partner

Novartis

Indication

Phase

ADCC mediated B cell depletion & BAFF-R blockade (AMBER)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Idiopathic pulmonary fibrosis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Systemic Lupus Erythematosus (SLE)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody 
  • Target: BAFF-R

Additional information:

NOV-8 (CMK389)

Partner

Novartis

Indication

Phase

Pulmonary Sarcoidosis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Severe Atopic Dermatitis
Phase 1 Phase 2 (Current Phase) Phase 3 Market

Setrusumab (BPS804)

Partner

Novartis/Mereo/Ultragenyx

Indication

Phase

Brittle bone disease (Type I, III, IV) (ASTEROID)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody 
  • Target: Sclerostin

Additional information:

Bimagrumab

Partner

Novartis/Versanis Bio

Indication

Phase

Type 2 diabetes
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody 
  • Target: ActRIIB
  • Aliases: BYM338

Additional information:

Utomilumab (PF-05082566)

Partner

Pfizer

Indication

Phase

Cancer (multiple indications)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody
  • Target: 4-1BB (CD137)
  • Alias: PF-05082566

Additional Information:

Xentuzumab (BI-836845)

Partner

Boehringer Ingelheim

Indication

Phase

Breast cancer
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Castration-resistant prostate cancer (CRPC) (combo with enzalutamide)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody
  • Target: IGF-1

Additional Information:

NOV-14 (CSJ117)

Partner

Novartis

Indication

Phase

Asthma
Phase 1 Phase 2 (Current Phase) Phase 3 Market
COPD
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • Target: TSLP

Additional Information:

Partner

I-Mab Biopharma**

Indication

Phase

Relapsed or refractory advanced solid tumors
Phase 1 (Current Phase) Phase 2 Phase 3 Market

* I-Mab receives exclusive rights in China, Hong Kong, Macao, Taiwan and South Korea, while MorphoSys retains rights in other parts of the world.